▲ S&P 500 +---% | ▲ Stock Advisor +---% Join The Motley Fool

Accessibility Log In Help

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Daily Stock Gainers Daily Stock Losers Most Active Stocks

Todd Campbell

XMFEBCapital

@ebcapital

Todd has been helping buy side portfolio managers as an independent researcher for over a decade. In 2003, Todd founded E.B. Capital Markets, LLC, a research firm providing action oriented ideas to professional investors. Todd has provided insight to a variety of publications, including SmartMoney, Barron's, and CNN/fn.

Recent Articles by Todd Campbell

Money spilling out of open bag GettyImages-92167268

Sep 11, 2017 by Todd Campbell, Dan Caplinger, and Demitri Kalogeropoulos

3 Stocks Warren Buffett Can't Buy, but You Can

Warren Buffett may not be able to invest Berkshire Hathaway's money into small-cap stocks, but that shouldn't stop you from considering upstarts Impinj, WisdomTree, and National Beverage.

gettyimages-513751936

Sep 8, 2017 by Todd Campbell

Why NewLink Genetics Is Soaring 37.5% Higher Today

Analysts weigh in with positive comments following updated mid-stage trial results for its IDO inhibitor.

lab scientists GettyImages-470913492

Sep 7, 2017 by Todd Campbell

Why Gene-Editing Pioneer Editas Skyrocketed 28.8% in August

Editas Medicine continues to make progress toward clinical trials of its gene-editing approach.

pills on money GettyImages-507799948

Sep 7, 2017 by Todd Campbell

AbbVie Scores 2 Wins: 1 Threatens Regeneron

AbbVie's patent portfolio got a reprieve, and positive data for AbbVie's eczema drug puts it on a collision course with Regeneron Pharmaceuticals' Dupixent.

Sep 7, 2017 by Todd Campbell

Are These Healthcare Stocks Top Takeover Targets?

Big-cap biopharma could come knocking if Juno Therapeutics’ next-generation CAR-T is safer than its competitors, and Medtronic's already investing billions in Mazor Robotics, a maker of surgical robots.

lab scientists 2 GettyImages-506712124

Sep 7, 2017 by Todd Campbell

Here's Why NewLink Genetics Is Vaulting 45% Higher Today

Updated mid-stage trial results for its IDO-inhibitor are sparking investor optimism.

gavel GettyImages-531254889

Sep 5, 2017 by Todd Campbell

What's Behind Mallinckrodt's 12.2% Tumble Today

Courts dealt the company a setback today on one of its best-selling drugs.

exact sciences

Sep 5, 2017 by Todd Campbell

Why Exact Sciences Shares Rallied 10.2% in August

Following better-than-expected second-quarter financials and an investor conference early in the month, Exact Sciences' stock posted double-digit gains in August.

syndros bottle

Sep 5, 2017 by Todd Campbell

Why This Marijuana Stock Crashed 18.5% in August

A lawsuit tied to the marketing of its fentanyl opioid spray caused Insys Therapeutics' shares to tumble last month.

Sep 5, 2017 by Todd Campbell

Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better

The FDA approved the world's first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion.

GettyImages-475177402

Sep 5, 2017 by Todd Campbell

Why Juno Therapeutics Shares Vaulted 46% Higher in August

Optimism is soaring following the FDA approval of Novartis' CAR-T and the $11.9 billion acquisition of CAR-T developer Kite Pharma.

GettyImages-487009046

Sep 4, 2017 by Todd Campbell

Don't Make This Big Mistake With Your Inheritance

Thinking about a lump-sum withdrawal? You might want to reconsider it after considering the tax consequences.

man with money falling getty-images-happy-retiree-raining-money_large

Sep 3, 2017 by Todd Campbell

Why Gilead Sciences Shares Soared 10.6% in August

A deal that puts the company at the cutting edge of cancer care has sparked investor enthusiasm.

retiree decision making GettyImages-200522108-001

Sep 1, 2017 by Todd Campbell

Lump Sum vs Pension: A Guide to Making the Right Choice for You

Deciding to take a pension or lump sum is a difficult decision, so before choosing, make sure you consider your budget, your health, and the tax risks.

market crash GettyImages-499578669

Sep 1, 2017 by Todd Campbell

What's Causing Health Insurance Innovations to Drop 12% Today?

Worries that healthcare reform could reduce demand for its health insurance products have sent shares tumbling.

business person worried GettyImages-474577567

Sep 1, 2017 by Todd Campbell

Saved Enough Money for Retirement? Think Again.

Rising costs in retirement will require people to save more money if they want to make ends meet.

businessman boxing GettyImages-496166842

Aug 31, 2017 by Todd Campbell

Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences

Ahead of Gilead Sciences completing its acquisition of CAR-T powerhouse Kite Pharma later this year, Novartis has secured FDA approval for its own CAR-T cancer therapy, and priced it at $475,000.

clock retirement savings GettyImages-622064048

Aug 31, 2017 by Todd Campbell, Dan Caplinger, and Demitri Kalogeropoulos

1 Stock I'm Never Selling

Vanguard Information Technology ETF, Celgene Corp., and Walt Disney are top stocks that investors can include in forever portfolios.

man with money falling getty-images-happy-retiree-raining-money_large

Aug 30, 2017 by Todd Campbell

Why Investors Bid Immunogen Inc. Up Almost 12% Today

Investors continued to warm up to the biotech's stock after news Tuesday of a licensing deal with Jazz Pharmaceuticals.

GettyImages-466997538

Aug 31, 2017 by Todd Campbell

3 Millionaire-Making Moves for Millennials

How important is it to invest in a retirement plan and limit your spending? Very, if your plans include becoming a millionaire.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services